Drugs / Abacavir/lamivudine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00549198 | Jun 2007 → Dec 2009 | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Abacavir/lamivudine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00549198 ↗ |
| Known as | KIVEXA | “Recently, the fixed-dose combinations (FDC) KIVEXA™ (abacavir/lamivudine) and TRUVADA (tenofovir disoproxil fumarate/emtricitabine) have facilitated the usage of once-daily regimens.” NCT00549198 ↗ |